INSIGHTS ON QUALITY CONTROL

• How To Double Up With A CDMO To Reduce Risk

  Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design.

• Build A Culture Of Clean To Elevate Your Cleanroom

  Keeping your cleanroom spotless is vital for product quality and patient safety. Consider these important factors for how to build a culture of clean and how your cleanroom will benefit.

• How Connected Bioanalytical Context Management Strengthens Bioanalytical Decision-Making

  Preserving data context across bioanalytical workflows improves decision-making, ensures complete traceability, speeds up study review cycles, and prepares datasets for advanced AI.

• Environmental Monitoring In Advanced Therapeutic Medicinal Products Facilities

  Discover how to adapt your environmental monitoring framework to meet the distinct risk-management and regulatory needs of ATMP facility production.

• 0.45 m/s ±20% At Working Position In Closed Sterility Testing Isolators: Requirement Or Convention?

  2/19/2026

  Balance compliance and efficiency in sterility testing. Explore how a risk-based approach to airflow and isolator technology aligns with Annex 1 while optimizing contamination control.

• Applying AI And Rapid Prototyping To Media And Process Development

  3/26/2026

  Hear from industry experts on how teams can integrate manufacturability considerations earlier through rapid prototyping, data-driven media development, and predictive modeling.

• Trend Analysis Of Particle Monitoring Data And Defining Alert And Action Limits

  9/9/2026

  Routine trend analysis of total and viable particle monitoring data helps identify operational shifts early, set statistical limits, and strengthen cleanroom contamination control strategies.

• From Manual To Automated QC: Key Considerations, Challenges, And Solutions

  8/25/2026

  Explore how rapid and automated QC methods can address staffing constraints, production growth, and regulatory demands while improving efficiency across biopharmaceutical laboratory operations.

• The Seamless Path To Market: End-To-End CDMOs As Your Strategic Ally Douglas CDMO

  5/14/2025

  Partner with an experienced end-to-end CDMO to streamline development, reduce risk, and accelerate your drug’s path to market in today’s complex and competitive pharmaceutical landscape.